Novo Nordisk , the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 ...

The Danish pharmaceutical company behind obesity drug Wegovy, Novo Nordisk, plans to invest US$1.09bn in expanding its ...

Novo Nordisk has invested 6.4bn Brazilian reais ($1.09bn) to expand its facility in Brazil as the company ramps up efforts to ...

Novo Nordisk (NVO), the company behind Ozempic ... Reinaldo Costa, the vice president of the Montes Claros factory, said this expansion will significantly increase the plant’s output, although ...

“Something that sells for $88 in London sells for $1,300 here, made in the same factory by the same company ... whose president is Novo Nordisk CEO Lars Fruergaard Jørgensen, said in a statement.

Novo Nordisk will invest $1.09 billion in Brazil to enhance production of injectable drugs for obesity and diabetes. This ...

In the sleepy suburb of Bagsværd, a 25-minute train ride from Denmark’s capital of Copenhagen, weight-loss drugmaker Novo Nordisk is everywhere. Street after street is filled with the company ...

Novo Nordisk (NYSE:NVO)) is going big in Brazil. The drugmaker behind Ozempic and Wegovy just dropped a $1.09 billion investment to supercharge its manufacturing plant in Montes Claros.